These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31999272)

  • 21. Psychosis and synthetic cannabinoids.
    Deng H; Verrico CD; Kosten TR; Nielsen DA
    Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: A case series.
    Barceló B; Pichini S; López-Corominas V; Gomila I; Yates C; Busardò FP; Pellegrini M
    Forensic Sci Int; 2017 Apr; 273():e10-e14. PubMed ID: 28190538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic cannabinoid use disorder: an update for general psychiatrists.
    Grigg J; Manning V; Arunogiri S; Lubman DI
    Australas Psychiatry; 2019 Jun; 27(3):279-283. PubMed ID: 30663326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing.
    Fox MA; Perry MC; Liu-DeRyke X
    Pharmacotherapy; 2020 Mar; 40(3):186-190. PubMed ID: 31995840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The synthetic cannabinoid 5F-MDMB-PICA: A case series.
    Kleis J; Germerott T; Halter S; Héroux V; Roehrich J; Schwarz CS; Hess C
    Forensic Sci Int; 2020 Sep; 314():110410. PubMed ID: 32683270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of recreational cannabinoids on peri-operative outcomes.
    Knackstedt R; Wu S; Gurunluoglu R
    J Plast Reconstr Aesthet Surg; 2020 Jan; 73(1):184-199. PubMed ID: 31213396
    [No Abstract]   [Full Text] [Related]  

  • 27. Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control - a prospective cohort study.
    Li J; Wang L; Chen F; Xia D; Miao L
    BMC Endocr Disord; 2018 Oct; 18(1):69. PubMed ID: 30285711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus.
    Davis A; Kuriakose J; Clements JN
    Clin Pharmacokinet; 2019 Apr; 58(4):421-430. PubMed ID: 29978361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic Marijuana and Synthetic Cannabinoid-Induced Toxic Myocarditis and End-Stage Cardiomyopathy: Management With Mechanical Circulatory Support as a Bridge-to-Transplantation.
    Hill GED; Izquierdo DA; Boettcher BT; Pagel PS
    J Cardiothorac Vasc Anesth; 2019 Sep; 33(9):2508-2512. PubMed ID: 30606509
    [No Abstract]   [Full Text] [Related]  

  • 30. Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections.
    Li FF; Fu LY; Zhang WL; Su XF; Wu JD; Sun J; Ye L; Ma JH
    J Diabetes Res; 2016; 2016():1028945. PubMed ID: 26839889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder.
    Cengel HY; Bozkurt M; Evren C; Umut G; Keskinkilic C; Agachanli R
    Psychiatry Res; 2018 Apr; 262():46-54. PubMed ID: 29407568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Historical and Current Perspectives of Synthetic Marijuana: Critical Review.
    Vera L; Bernstein K; Lee S
    J Addict Nurs; 2020; 31(2):85-91. PubMed ID: 32487934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical Illness Secondary to Synthetic Cannabinoid Ingestion.
    Kourouni I; Mourad B; Khouli H; Shapiro JM; Mathew JP
    JAMA Netw Open; 2020 Jul; 3(7):e208516. PubMed ID: 32687586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of mixing glargine and short-acting insulin analogs on glucose control.
    Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA
    Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016
    [No Abstract]   [Full Text] [Related]  

  • 35. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
    Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
    Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Spiceophrenia": a systematic overview of "spice"-related psychopathological issues and a case report.
    Papanti D; Schifano F; Botteon G; Bertossi F; Mannix J; Vidoni D; Impagnatiello M; Pascolo-Fabrici E; Bonavigo T
    Hum Psychopharmacol; 2013 Jul; 28(4):379-89. PubMed ID: 23881886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.
    Zijlstra E; Demissie M; Graungaard T; Heise T; Nosek L; Bode B
    J Diabetes Sci Technol; 2018 Jan; 12(1):145-151. PubMed ID: 28918652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine.
    King AB; Clark D; Wolfe GS
    Endocr Pract; 2012; 18(4):558-62. PubMed ID: 22548951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The health threat of new synthetic opioids as adulterants of classic drugs of abuse.
    Rinaldi R; Negro F; Minutillo A
    Clin Ter; 2020; 171(2):e107-e109. PubMed ID: 32141480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical effects of reported synthetic cannabinoid exposure in patients admitted to the intensive care unit.
    Tatusov M; Mazer-Amirshahi M; Abbasi A; Goyal M
    Am J Emerg Med; 2019 Jun; 37(6):1060-1064. PubMed ID: 30146395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.